Actinogen Medical Completed XanaMIA Clinical Trial
The pharmaceutical company has finished the final patient visits for its Alzheimer's disease treatment study.
Updated on Sept. 23, 2026 in Alzheimer’s
Live Poll
Are you confident that current medical research is effectively addressing the progression of Alzheimer's disease?
Actinogen Medical has concluded the final patient visit for its XanaMIA clinical trial, which investigated the drug Xanamem for Alzheimer's treatment. The company now prepares to analyze data from the 247-participant study.
Why it matters
The study tests whether a 10-milligram daily dose of Xanamem can slow Alzheimer's progression by controlling cortisol levels in the brain. If successful, this approach could offer a new therapeutic pathway for disease management.
The study enrolled 247 participants with an average age of 75, including 66% who carry the ApoE4 genetic risk factor and 49% women. The trial utilized pTau181 biomarker blood testing for patient selection.
The players
Actinogen Medical
An Australian biotechnology firm focused on developing innovative therapies for neurological and neuropsychiatric diseases.
The details
Researchers evaluated disease progression over a 36-week period using the Clinical Dementia Rating scale sum of boxes. Participants were split between those receiving the active 10-milligram dose of Xanamem and those receiving a placebo.
Timeline
The clinical study required a 36-week duration for each participant.
The final patient visit for the trial was completed in September 2026.
Topline clinical results are currently expected in November 2026.
Health Landscape
This trial utilizes the pTau181 biomarker blood testing protocol to enhance the accuracy of participant screening compared to older cognitive assessment standards. It marks a shift toward precision diagnostics in neurodegenerative drug development.
The completion of this trial moves the drug Xanamem one step closer to potential availability for patients struggling with Alzheimer's disease. Results from this study will help determine if this daily pill can become a viable option for managing the condition.
The takeaway
The successful conclusion of this trial brings the medical community closer to understanding if cortisol regulation in the brain can effectively alter dementia trajectories. Patients and caregivers should continue to monitor clinical developments for new treatment options expected in late 2026.
What happens next
The company expects to release topline trial results in November 2026.
Further reading
Learn more about current research into Alzheimer’s treatments and therapeutic breakthroughs.
Live Poll
Are you confident that current medical research is effectively addressing the progression of Alzheimer's disease?
